IMPORTANCE Alternate-day fasting has become increasingly popular, yet, to date, no long-term randomized clinical trials have evaluated its efficacy.
T he first-line therapy prescribed to obese patients for weight loss is daily calorie restriction. 1 However, many patients find it difficult to adhere to a conventional weight-loss diet because food intake must be limited every day. 2 As such, adherence to daily calorie restriction decreases after 1 month and continues to decline thereafter. [3] [4] [5] In light of this limitation, another approach that requires individuals to restrict calories only every other day was developed. 6 This strategy is called alternate-day fasting and involves a fast day where individuals consume 25% of their usual intake (approximately 500 kcal), alternated with a "feast day" where individuals are permitted to consume food ad libitum. Findings from short-term studies indicate that participants lose 3% to 7% of body weight after 2 to 3 months of alternate-day fasting and experience improvements in lipid profiles, blood pressure, and insulin sensitivity.
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Alternate-day fasting regimens have increased in popularity during the past decade, and several best-selling diet books 14, 15 have promoted this approach. More than 1 million copies of these books have been sold in the United States and United Kingdom to date. Despite the growing popularity of alternate-day fasting, to our knowledge, no long-term randomized clinical trials have evaluated its efficacy or compared this regimen with a conventional weight-loss diet.
We conducted a 1-year, randomized clinical trial to compare the effects of alternate-day fasting vs daily calorie restriction on body weight and risk indicators for cardiovascular disease. We hypothesized that the participants in the alternateday fasting group would be more adherent to their diet, achieve greater weight loss, and experience more pronounced improvements in risk indicators for cardiovascular disease during the 6-month weight-loss phase compared with those in the daily calorie restriction group. We also hypothesized that the alternate-day fasting group would better maintain their weight loss and sustain their improvements in risk indicators for cardiovascular disease during the 6-month weight-maintenance phase compared with the daily calorie restriction group.
Methods

Participants
We conducted the trial between October 1, 2011, and January 15, 2015, at the University of Illinois at Chicago. Participants were recruited from the Chicago area by means of flyers placed around the university and were screened via a questionnaire, an assessment of body mass index, and a pregnancy test. Individuals included were men and women between 18 and 65 years of age, with a body mass index between 25.0 and 39.9 (calculated as weight in kilograms divided by height in meters squared) who had previously been sedentary (<60 minutes per week of light activity for the 3 months prior to the study). Exclusion criteria were a history of cardiovascular disease or type 1 or 2 diabetes, use of medications that could affect study outcomes, unstable weight for 3 months prior to the beginning of the study (>4-kg weight loss or gain), perimenopause or otherwise irregular menstrual cycle, pregnancy, and currently smoking. The protocol was approved by the Office for the Protection of Research Subjects at the University of Illinois at Chicago, and written informed consent was obtained from all participants. The full protocol is available in Supplement 1.
Randomization and Intervention Groups
Participants were randomized in a 1:1:1 ratio to an alternateday fasting group, daily calorie restriction group, or nointervention control group. Randomization was performed by a stratified random sampling procedure by sex, age (18-42 years and 43-65 years), and body mass index (25.0-32.5 and 32.6-39.9). Block size ranged from 1 to 11 participants. The active trial duration was 1 year and consisted of a baseline phase (1 month), a weight-loss phase (6 months), and a weightmaintenance phase (6 months) (eFigure 1 in Supplement 2). We chose this design because weight loss typically peaks at 6 months during a lifestyle intervention. 16 During the baseline phase, all participants ate their usual diet and maintained a stable weight. Baseline total energy expenditure was measured using doubly labeled water. 17 All participants were instructed not to change their physical activity habits throughout the trial (eg, not to join a gym) to avoid potential confounding.
Weight-Loss Phase
Participants in the alternate-day fasting group and those in the daily calorie restriction group were provided with all meals during the first 3 months of the trial and received dietary counseling thereafter (eFigure 1 in Supplement 2). During the 6-month weight-loss phase, the intervention groups were instructed to reduce their energy intake by a mean of 25% per day. To achieve this reduction, the alternate-day fasting group was instructed to consume 25% of baseline energy intake as a lunch (between 12 PM and 2 PM) on fast days and 125% of baseline energy intake split between 3 meals on alternating feast days. The daily calorie restriction group was instructed to consume 75% of baseline energy intake split between 3 meals every day. The provided meals were in accordance with the American Heart Association guidelines 18 for macronutrient intake, with 30% of energy as fat, 55% as carbohydrate, and 15% as protein.
From months 4 to 6, when food was no longer provided, intervention participants met individually with a dietician or nutritionist weekly to learn how to continue with their diets on their own.
Weight-Maintenance Phase
At the beginning of the 6-month weight-maintenance phase, total daily energy expenditure was reassessed using doubly labeled water. 17 Participants were instructed to maintain their body weight during this phase. Participants in the alternate-day fasting group were instructed to consume 50% of energy needs as a lunch on fast days and 150% of energy needs split between 3 meals on alternating feast days. Participants in the daily calorie restriction group were instructed to consume 100% of energy needs split between 3 meals every day. Intervention participants met with the dietician individually each month to learn cognitive behavioral strategies to prevent weight regain 19 and received personalized energy targets for weight maintenance based on results from doubly labeled water.
Control Group Protocol
Participants in the control group were instructed to maintain their weight throughout the trial and not to change their eating or physical activity habits. Controls received no food or dietary counseling but visited the research center at the same frequency as the intervention participants (to provide outcome measurements). Controls who completed the 12-month trial received 3 months of free weight-loss counseling and a 12-month gym membership at the end of the study.
Outcome Measures
The primary outcome of the study was change in body weight, which was measured monthly via a digital scale while the participant was in a hospital gown. Fat mass and lean mass were measured every 6 months in the fasted state by dual-energy x-ray absorptiometry (QDR 4500W; Hologic). Visceral fat mass was measured every 6 months by magnetic resonance imaging performed with a 1.5-T magnet (Siemens Vision), and images were analyzed using validated software.
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Mean percentage energy restriction during the weightloss phase was retrospectively calculated by the intake balance method using doubly labeled water and changes in body composition. 21 Physical activity was measured for 7 consecutive days every 6 months using an activity monitor (SenseWear Armband Mini; BodyMedia Inc). 22 Dietary intake and adherence to diets was assessed every 3 months with a 7-day food record and analyzed using Nutritionist Pro software (Axxya Systems LLC). Intervention participants were considered to be adherent when their actual energy intake, determined via food records, was within 200 kcal of their prescribed daily energy goal. Blood samples were obtained following a 12-hour fast every 6 months (collected on the morning after a feast day for the alternate-day fasting group). Secondary outcomes included blood pressure, heart rate, and total cholesterol, lowdensity lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting glucose, fasting insulin, C-reactive protein, and homocysteine concentrations (analytical methods are detailed in the full protocol in Supplement 1). The homeostasis model assessment of insulin resistance was calculated as insulin × glucose/405, where the unit of measure for insulin is in micro-international units per milliliter and the unit of measure for glucose is milligrams per deciliter.
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Statistical Analysis
For the sample size calculation, we estimated that alternateday fasting would reduce body weight by 15% by month 6 9, 11 and that daily calorie restriction would reduce body weight by 10% by month 6. 24 We calculated that 26 participants per group would provide 80% power to detect a significant difference of 5% in body weight between the alternate-day fasting group and the daily calorie restriction group at month 6, using a 2-tailed independent-samples t test with α = .05. We anticipated a dropout rate of 12%. Thus, we initially aimed to recruit 90 participants (30 per group), assuming that 78 participants (26 per group) would complete the trial. We later decided to recruit 100 participants to increase our statistical power because our dropout rate was higher than expected. Data are shown as mean values (with 95% CIs) unless otherwise noted. A 2-tailed P < .05 was considered statistically significant. Tests for normality were included in the model, and all data were found to be normally distributed. We conducted an intention-to-treat analysis, which included data from all 100 participants who underwent randomization. Results are reported by intention-to-treat analysis unless indicated otherwise. A linear mixed model was used to assess time, diet, and time × diet effects for each outcome. This model provides unbiased estimates of time and treatment effects under a missingat-random assumption. Time was not assumed to be linear in the model. This strategy allowed for estimation of time and diet effects (and their interaction) without imposing a linear time trend. The analyses were performed using SAS, version 9.4 (SAS Institute, Inc), and R software, version 3.2.2 (R Foundation for Statistical Computing).
Results
Participant Characteristics and Attrition
Of the 222 participants who were screened, 100 (45.0%) were randomly assigned to the diet or control groups, and 69 (69.0% of those assigned) completed the study (Figure 1 ). The dropout rate was highest in the alternate-day fasting group (13 of 34 [38%]), relative to the daily calorie restriction group (10 of 35 [29%]) and control group (8 of 31 [26%] ). More participants in the alternateday fasting group than in the daily calorie restriction group withdrew owing to difficulties adhering with the diet. All baseline characteristics had comparable distributions between the alternate-day fasting group, the daily calorie restriction group, and the control group ( Table 1) . The participants were primarily metabolically healthy obese women.
Prescribed vs Actual Energy Intake Determined via Food Records
On the fast day (Figure 2A) , participants in the alternate-day fasting group exceeded their prescribed energy goal at months 3 and 6. On the feast day ( Figure 2B ), participants in the alternate-day fasting group ate less than their prescribed goal at months 3, 6, 9, and 12. Participants in the daily calorie restriction group ( Figure 2C ) met their prescribed energy goals at months 3, 6, and 12 but ate less than their prescribed goal at month 9. A higher proportion of participants in the daily calo-rie restriction group were adherent to their energy goals at months 3, 6, 9, and 12 relative to those in the alternate-day fasting group.
Percentage Energy Restriction Determined via Doubly Labeled Water
From baseline to month 6, the alternate-day fasting group achieved a mean (SD) percentage energy restriction of 21% (16%), and the daily calorie restriction group achieved a mean (SD) percentage energy restriction of 24% (16%), with no significant difference between the intervention groups or compared with the control group (eFigure 2 in Supplement 2).
Physical Activity and Dietary Intake
Data on dietary intake are displayed in eTable 1 in Supplement 2. Percentage of energy intake from fat, carbohydrates, and protein did not differ significantly over time in any of the groups. Physical activity, measured as steps per day, did not change during the course of the trial in any group (eTable 2 in Supplement 2). This level of activity is approximately 1000 to 2000 steps per day higher than that of the average overweight or obese adult. 25 
Weight Loss and Weight Maintenance
Changes in body weight are displayed in Figure 3 and Table 2 . Weight loss was not significantly different between the alternate-day fasting group and the daily calorie restriction group at month 6. At the end of the study, total weight loss was -6.0% (95% CI, -8.5% to -3.6%) for the alternate-day fasting group and -5.3% (95% CI, -7.6% to -3.0%) for the daily calorie restriction group, relative to controls, with no significant difference between the intervention groups. Weight regain from months 6 to 12 (-0.8%; 95% CI, -3.2% to 1.7%) was not significantly different between the alternate-day fasting group and the daily calorie restriction group. Moreover, weight regain from months 6 to 12 was not significantly different between the alternate-day fasting group and controls (0.8%; 95% CI, -1.8% to 3.3%), or the daily calorie restriction group and controls (1.5%; 95% CI, -0.8% to 3.9%). Changes in body composition are reported in Table 2 . There were no statistically significant differences between the alternate-day fasting group and the daily calorie restriction group for fat mass, lean mass, or visceral fat mass at month 6 or month 12.
Blood Pressure and Heart Rate
Blood pressure was not significantly different between the intervention groups, or relative to controls, at month 6 or month 12 (Table 2 ). There were also no statistically significant differences in heart rate between the alternate-day fasting group and the daily calorie restriction group at month 6 or month 12 (Table 2) .
Plasma Lipids
Changes in plasma lipids during the course of the trial are shown in Table 2 . Total cholesterol levels were not significantly different between the intervention groups, or relative to controls, at month 6 or month 12. At month 6, high-density lipoprotein cholesterol levels were significantly elevated in the alternate-day fasting group by 6.2 mg/dL (95% CI, 0.1-12.4 mg/ dL) (to convert to millimoles per liter, multiply by 0.0259) vs the daily calorie restriction group, but this effect was no longer observed by month 12. Low-density lipoprotein choles- terol concentrations did not differ significantly between the intervention groups at month 6. At month 12, low-density lipoprotein cholesterol levels significantly increased in the alternate-day fasting group (11.5 mg/dL [95% CI, 1.9-21.1 mg/ dL]) (to convert to millimoles per liter, multiply by 0.0259) relative to the daily calorie restriction group. Triglyceride levels did not differ significantly between the intervention groups at month 6 or month 12.
Glucoregulatory and Inflammatory Factors
Changes in glucoregulatory and inflammatory factors are displayed in Table 2 . Fasting plasma glucose did not differ significantly between the intervention groups, or relative to controls, at month 6 or month 12. There were also no significant differences in fasting insulin or the homeostasis model assessment of insulin resistance between the intervention groups at month 6 or month 12. High-sensitivity C-reactive protein and homocysteine levels did not differ significantly between the intervention groups, or relative to controls, at month 6 or month 12. We also performed a sensitivity analysis, in which sex and race/ethnicity were included as adjustment covariates in the intention-to-treat mixed model. The inclusion of sex and race/ethnicity did not affect any of the estimated treatment effects reported in Table 2 .
Discussion
The results of this randomized clinical trial demonstrated that alternate-day fasting did not produce superior adherence, weight loss, weight maintenance, or improvement in risk indicators for cardiovascular disease compared with daily calorie restriction. Alternate-day fasting has been promoted as a potentially superior alternative to daily calorie restriction under the assumption that it is easier to restrict calories every other day. However, our data from food records, doubly labeled water, and regular weigh-ins indicate that this assumption is not the Actual energy intake assessed via a 7-day food record at baseline and months 3, 6, 9, and 12. A, Actual energy intake assessed via a 7-day food record at baseline and months 3, 6, 9, and 12 in the alternate-day fasting group on the fast day was significantly (P < .05) higher than the prescribed energy goal at months 3 and 6. B, Actual energy intake assessed via a 7-day food record at baseline and months 3, 6, 9, and 12 in the alternate-day fasting group on the feast day was significantly lower (P < .001) than the prescribed energy goal at months 3, 6, 9, and 12. C, Participants in the daily calorie restriction group met their prescribed energy goal at months 3, 6, and 12. At month 9, actual energy intake in the daily calorie restriction group was significantly lower (P < .05) than the prescribed energy goal. Data are expressed as mean (SD) values; only observed values were included. The weight-loss period was from baseline to month 6; the weight-maintenance period was from month 6 to month 12. Error bars indicate 95% CI.
a Significant difference between prescribed energy intake and actual energy intake at a particular month in the study. case. Rather, it appears as though many participants in the alternate-day fasting group converted their diet into de facto calorie restriction as the trial progressed. Moreover, the dropout rate in the alternate-day fasting group (38%) was higher than that in the daily calorie restriction group (29%) and the control group (26%). It was also shown that more participants in the alternate-day fasting group withdrew owing to dissatisfaction with diet compared with those in the daily calorie restriction group ( Figure 1 ). Taken together, these findings suggest that alternate-day fasting may be less sustainable in the long term, compared with daily calorie restriction, for most obese individuals. Nevertheless, it is still possible that a certain smaller segment of obese individuals may prefer this pattern of energy restriction instead of daily restriction. It will be of interest to examine what behavioral traits (eg, ability to go for long periods without eating) make alternate-day fasting more tolerable for some individuals than others. To our knowledge, the present study is the longest and largest trial of alternate-day fasting to date. Previous trials of alternate-day fasting reported weight loss of 3% to 7% after 2 to 3 months of diet.
7-13 Adherence was measured in several previous trials and was shown to be high (eg, participants met their calorie goals on approximately 80%-90% of fast days).
7,8,10,11
Most of these past studies provided food on the fast day, 7, 8, 10, 11 so the provision of food is not a confounder when comparing past findings with present findings. Food was provided to the intervention participants during the first 3 months of the weight-loss phase to promote adherence 26 and show participants the types and quantities of foods that they should be eating. Data from the food records indicated that participants frequently ate extra "nonstudy" foods that were purchased from stores or restaurants. This finding suggests that limiting caloric intake to approximately 500 kcal every other day may have been difficult for many participants early in the intervention. Future work in this area should examine whether this lack of adherence to alternate-day fasting is due to cognitive, environmental, and/or physiological factors. For instance, measuring changes in subjective appetite (hunger and fullness) in conjunction with modulations in appetite hormones (ghrelin, peptide YY, and glucagon-like peptide-1) could offer some insight into why daily calorie restriction may allow for easier adherence compared with alternate-day fasting. Contrary to our original hypotheses, the participants in the alternate-day fasting group did not experience more pronounced improvements in risk indicators for cardiovascular disease compared with the participants in the daily calorie restriction group. However, the trial included primarily metabolically healthy obese adults. Since many of the participants had normal cholesterol levels and normal blood pressure at baseline, it is not surprising that most risk indicators for cardiovascular disease did not change in response to diet.
Limitations
Our study has several limitations. First, the duration of the maintenance phase was short (6 months). Second, the control group was imperfect, in that they received no food, no counseling, and less attention from study personnel, relative to the intervention groups, which may have confounded our findings. We also failed to include the control group in our initial power calculation. Third, since the dropout rate was higher than anticipated, our power to detect the hypothesized difference of 5% weight loss between the intervention groups at month 6 decreased from 80% to 60%. The higher dropout rate in the alternate-day fasting group may have also introduced a possible selection bias between groups. 27 Finally, we enrolled predominantly metabolically healthy obese individuals, which may have hindered the abilities of the interventions to produce greater improvements in our measured cardiovascular disease risk indicators. 28, 29 The generalizability of our findings is also limited by the enrollment.
Conclusions
The alternate-day fasting diet was not superior to the daily calorie restriction diet with regard to adherence, weight loss, weight maintenance, or improvement in risk indicators for cardiovascular disease. 
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week randomized, controlled, parallel-arm feeding trial will be implemented to test these objectives. The 32 trial will be divided into 3 consecutive intervention periods: (1) 4-week baseline; (2) 24-week weight loss
33
with food provided for 12-weeks; and (3) 24-week weight maintenance with no food provided. Overweight
34
and obese subjects (n = 90) will be randomized to 1 of 3 groups: (1) ADF, 75% energy restriction on the
35
"fast day" and 125% energy intake on the "feed day"; (2) CR, 25% restriction everyday; or 3) control,
36
100% energy intake everyday. During the weight maintenance phase, ADF subjects will consume 50% of 37 their energy needs on the "fast day" and 150% of energy needs on the "feed day", while CR and control 38 subjects will consume 100% of their needs everyday. . As such, these fat cell parameters are now considered "emerging" indicators of CHD risk.
67
Whether greater reductions in body weight after 24 weeks of ADF can produce more pronounced 
71
that has yet to be addressed. Accordingly, the specific aims of the proposed study are:
73
Specific aim 1: To establish that adherence to ADF is greater than that of CR during a 24-week 74 intervention period and to determine if increased adherence to ADF results in greater weight loss.
76
Hypothesis 1: ADF subjects will be more adherent with diet than CR subjects, resulting in greater 77 energy restriction and weight loss by ADF when compared to CR. 
90
Hypothesis 3: ADF subjects will maintain their post-reduction body weight and sustain their 91 improvements in CHD risk, while CR subjects (on a weight maintenance diet) will regain weight and 
125
body weight is required to lower systolic and diastolic blood pressure 15, 16 . As for plasma LDL cholesterol,
126
and triglycerides, a 10% weight loss is needed [17] [18] [19] [20] . In order to increase HDL cholesterol and decrease
127
CRP, a 15% weight loss is required 17, 21, 22 . Thus, in order to improve all of these traditional risk factors,
128
15% weight loss is optimal.
130 Degree of weight loss required to reduce CHD risk and role of ADF versus CR (Specific aim 2). 131
The majority of CHD risk indicators only improve with 15% weight loss. In view of our pilot findings, we
132
hypothesize that ADF subjects will be more adherent with diet, and will experience a 15% weight loss by 133 24 weeks. Based on the literature [4] [5] [6] , the CR group will not achieve a 15% weight loss by week 24. This . We hypothesize that preserving the ADF meal pattern without restricting 141 energy, will help these subjects self-monitor energy intake and augment dietary restraint. These 142 behavioral changes that occur with ADF will assist these individuals in preventing weight regain. on physiological variables, and show that ADF is more effective than CR for weight loss, weight 153 maintenance, and CHD risk reduction. In sum, the proposed study is innovative in that it will be the first candidates for weight loss therapy, and 2) at risk for developing CHD, thus any influence of diet on CHD 174 risk should be readily observable.
175 176 5.3 Exclusion criteria. Subjects excluded from participating in the study include those who: 177
• Have a history cardiovascular disease (prior angina, myocardial infarction or stroke)
178
• Are diabetic (fasting blood glucose > 126 mg/dl)
179
• Are taking anti-depressant or anti-anxiety medications
180
• Are taking drugs that affect study outcomes (weight loss medications)
181
• Are not weight stable for 3 months prior to the beginning of study (weight gain or loss > 4 kg)
182
• Are not able to keep a food diary or activity log for 7 consecutive days during screening
183
• Are perimenopausal or have an irregular menstrual cycle (menses that does not appear every 27-32 184 days)
185
• Are claustrophobic or have implanted electrical devices (cardiac pacemaker or a neurostimulator)
186
• Are pregnant, or trying to become pregnant 
193
is an indicator of a diagnosed psychiatric disorder, thus these individuals will be excluded. Moreover,
194
individuals taking drugs to control body weight will be excluded, as these medications may confound the 195 effect of diet on the key outcome measure. Subjects who are not weight stable will be excluded since a
196
weight stable baseline must be set in order to attribute physiological effects to the intervention.
197
Individuals who are unable to adequately report dietary intake or physical activity will also be excluded.
198
Being perimenopausal, or having long or irregular menstrual cycles may be associated with altered lipid 
210
Since this is a very time-intensive trial, the purpose of Visit 2 (scheduled 10 d after the first screening) is
211
to evaluate each subject's motivation to participate in the study. As such, subjects who do not attend the 212 second visit, or who do not adequately complete 7-d food and physical activity records, will be excluded.
213
Written informed consent will be obtained prior to screening.
215
Randomization: Subjects will be randomized by the Biostatistician, Dr. Sally Freels, Ph.D., by way of a 216 stratified random sample. The sample frame will be divided into strata based on BMI, sex, age. Subjects 217 from each stratum, will then be randomized to 1 of 3 groups: 1) ADF, 2) CR, or 3) control. 
242
will be assessed at the beginning and end of this period.
244 Weight loss/ dietary intervention period (24 weeks):
After this period, subjects will be randomized into 245
1 of 3 groups. Food will be provided from weeks 1-12 in the ADF and CR groups. All diets will be 246 prepared in the metabolic kitchen of the Human Nutrition Research Center. Study diets will be formulated 247 for each participant using Nutritionist Pro (Axxya Systems). The diets will be provided as a 3-day rotating 248 menu, and will be formulated based on the American Heart Association (AHA) guidelines (30% kcal from 249 fat, 15% from protein, 55% from carbohydrate). All meals will be consumed outside of the research 250 center. Participants will be requested to eat only the foods provided on calorie-restriction days and to
251
bring back any leftover foods. Subjects will be advised to drink plenty of water. Calorie-free foods (i.e.
252
black coffee, diet sodas) will be permitted as desired. During weeks 13-24, food will no longer be 253 provided. Instead, ADF and CR subjects will attend weekly dietary counseling sessions where they will 254 learn how to follow their diet on their own at home.
255
• ADF weight loss protocol: Food will be provided on the feed and fast days during weeks 1-12. ADF 256 subjects will be energy restricted by 75% of their TEE on the fast day and eat 125% of needs on the 257 feed day. Fast day meals will be consumed between 12.00 pm and 2.00 pm to ensure that each ADF 258 subject is fasting for the same duration. For the following 12-weeks (weeks 13-24), only dietary 259 counseling will be provided, and ADF subjects will be energy restricted by 75% of their TEE on the fast 260 day and eat food ad libitum on the feed day.
261
• CR weight loss protocol: CR subjects will be restricted by 25% of their TEE every day, and will be 262 provided with all calorie-restricted meals.
263
• Control diet protocol: Control subjects will eat ad libitum at home every day, but will visit the research 264 center at the same frequency as the treatment groups to alleviate investigator-interaction bias between 265 groups.
267 268
Visits to the research center. From week 1 to 24, subjects will visit the research center once per week 269 for meal pickup and clinical measurements (total of 24 visits). All study activities will take place on 1 day 270 per week to minimize subject burden. The trial will be staggered so that subjects will be recruited in 9
271
overlapping stages. At each stage, n = 3-4 ADF, n = 3-4 CR, and n = 3-4 control subjects will be 272 recruited (n = 10 subjects will begin at the same time at each stage). 
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Weight maintenance period (24 weeks): During this phase, all subjects will visit the research center at 288 4-week intervals. ADF and CR subjects will maintain their post-reduction body weight by attending 289 dietary counseling sessions (no food will be provided). Weight-maintenance energy requirements (TEE)
290
will be reassessed by the DLW at the beginning of this period. The Dietician will meet with ADF and CR 291 subjects to develop individualized weight maintenance meal plans. These plans will include menus,
292
portion sizes, and food lists that are consistent with their food preferences and prescribed calorie levels 293 for weight maintenance. Food scales will be provided to help with appropriate portioning. Participants will 294 meet with the Dietician every 4 weeks throughout this period to review and modify the meal plans. During 295 these sessions, subjects will also be instructed how to make general healthy food choices that conform 296 to AHA guidelines and learn behavioral weight maintenance techniques.
297
• ADF weight maintenance protocol: ADF subjects will consume 50% of their post-reduction TEE on 298 the fast day and eat ad libitum on the feed day to maintain body weight. Fast day meals will be 299 consumed between 12.00pm and 2.00 pm to ensure similar fasting durations between subjects.
300
• CR weight maintenance protocol: CR subjects will eat 100% of their TEE to maintain body weight.
301
• Control diet protocol: Control subjects will eat ad libitum at home every day, but will visit the research . Blood pressure will be 361 assessed every week after the weigh-in following a 10 min rest. C-reactive protein: Plasma CRP 362 concentrations will be measured by a commercially available, highly sensitive assay (Behring Diagnosis,
363
Westwood, Mass).
365
Measurement of emerging CHD risk factors
366
Adipokine plasma levels: Plasma adiponectin, leptin, and resistin concentrations will be measured by 367 commercially available ELISA kits (R&D Systems, Minneapolis, MN). Samples will be assessed in 368 duplicate. Body fat distribution: Subcutaneous and visceral fat mass will be assessed at 24-week 369 intervals by magnetic resonance imaging (MRI). MRI scans will be performed at the Center for Magnetic
370
Resonance Research (located 3 blocks from the research center). Images will be obtained using a 3.0
371
Tesla MRI scanner. Briefly, the subjects will be placed in a prone position, and the scan will be 372 conducted in two parts: 1) upper body scan, and 2) lower body scan, as described previously 
374
All MRI data will be analyzed using the Hippo Fat program. 
396
measures ANOVA. Data will be analyzed using SAS software (version 9.2; SAS Inc., Cary, NC).
398
The intention-to-treat analysis will include data from all participants who underwent randomization, and
399
the last recorded value will be carried forward in the case of missing data for all variables. The 400 completion analysis will include all participants for whom data will be available from the time of 
